Ascendis Pharma/$ASND
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Ascendis Pharma
Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology, which includes TransCon PTH, TransCon CNP, and others. It operates in the United States, Europe, and the rest of the world and derives the majority of its revenue from the United States.
- Ticker
- $ASND
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 1,189
- Headquarters
- Hellerup, Denmark
- Website
- ascendispharma.com
Ascendis Pharma Metrics
BasicAdvanced
$17B
19.98
$12.98
-
-
Price and volume
Market cap
$17B
52-week high
$282.15
52-week low
$203.80
Average daily volume
703K
Financial strength
Current ratio
2.991
Quick ratio
2.229
Long term debt to equity
0.268
Total debt to equity
0.313
Interest coverage (TTM)
2.01%
Profitability
EBITDA (TTM)
291.873
Gross margin (TTM)
91.30%
Net profit margin (TTM)
70.84%
Operating margin (TTM)
24.70%
Effective tax rate (TTM)
-658.14%
Revenue per employee (TTM)
$974,920
Management effectiveness
Return on assets (TTM)
9.58%
Return on equity (TTM)
118.78%
Valuation
Price to earnings (TTM)
19.976
Price to revenue (TTM)
13.857
Price to book
11.85
Price to tangible book (TTM)
11.88
Price to free cash flow (TTM)
43.294
Free cash flow yield (TTM)
2.31%
Free cash flow per share (TTM)
5.989
Growth
Revenue change (TTM)
113.35%
Earnings per share change (TTM)
-356.73%
3-year revenue growth (CAGR)
106.35%
10-year revenue growth (CAGR)
66.26%
3-year earnings per share growth (CAGR)
2.54%
10-year earnings per share growth (CAGR)
18.61%
What the Analysts think about Ascendis Pharma
Analyst ratings (Buy, Hold, Sell) for Ascendis Pharma stock.
Analyst projections of the future price of Ascendis Pharma stock.
Bulls say / Bears say
Second-quarter product revenue more than doubled year on year to €315 million, led by YORVIPATH, while non-IFRS operating profit reached €92 million. That suggests the commercial business is scaling beyond its earlier development-stage profile. (Ascendis Pharma)
YUVIWEL has a positive recommendation from the EMA’s medicines committee for use in children with achondroplasia, with a final EU decision expected in Q4 2026. Approval could open another market for a product already launched in the US. (BioSpace)
Early combination-trial results showed growth efficacy above the 97th percentile for children of average stature through 78 weeks, with all 21 children still on treatment. If larger trials confirm the result, the combination could broaden Ascendis’ achondroplasia opportunity beyond YUVIWEL alone. (SEC)
Ascendis agreed to pay BioMarin royalties of 20% of YUVIWEL net sales in the US and 18% in several other markets through May 2030. Those payments will reduce the product’s sales contribution and leave less upside from a successful launch. (SEC)
Novo Nordisk ended its collaboration on metabolic and cardiovascular programmes, including monthly TransCon Semaglutide. Ascendis now plans to pursue the programme itself, taking on development costs and execution risk without the former partner’s potential milestone and royalty support. (Fierce Biotech)
Ascendis stopped internal development of its oncology drug onvapegleukin alfa, saying the work did not fit its strategic focus. This reduces diversification and leaves the investment case more reliant on endocrinology products and programmes. (BioSpace)
Data summarised monthly by Lightyear AI. Last updated on 8 Nov 2026.
Ascendis Pharma Financial Performance
Revenues and expenses
Ascendis Pharma Earnings Performance
Company profitability
Upcoming events
No upcoming events
Ascendis Pharma News
AllArticlesVideos
Funds containing Ascendis Pharma
Fund name | Fund size | $ASND weighting |
|---|---|---|
iShares Nasdaq US Biotechnology£BTEK | $1.3B | 1.00% |
iShares Nasdaq US Biotechnology$BTEC | $1.3B | 1.00% |
iShares Russell 1000 Growth$R1GR | $1.3B | 0.04% |
iShares Russell 1000 Growth£R1GB | $1.3B | 0.04% |
iShares Russell 1000 Growth$R1GR | $1.3B | 0.04% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.